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Chronic pain can develop in response to conditions such as inflammatory arthritis. The central mecha-
nisms underlying the development and maintenance of chronic pain in humans are not well elucidated
although there is evidence for a role of microglia and astrocytes. However in pre-clinical models of pain,
including models of inflammatory arthritis, there is a wealth of evidence indicating roles for pathological
glial reactivity within the CNS. In the spinal dorsal horn of rats with painful inflammatory arthritis we
found both a significant increase in CD11b+ microglia-like cells and GFAP+ astrocytes associated with
blood vessels, and the number of activated blood vessels expressing the adhesion molecule ICAM-1, indi-
cating potential glio-vascular activation. Using pharmacological interventions targeting VEGFR2 in
arthritic rats, to inhibit endothelial cell activation, the number of dorsal horn ICAM-1+ blood vessels,
CD11b+ microglia and the development of secondary mechanical allodynia, an indicator of central sensi-
tization, were all prevented. Targeting endothelial VEGFR2 by inducible Tie2-specific VEGFR2 knock-out
also prevented secondary allodynia in mice and glio-vascular activation in the dorsal horn in response to
inflammatory arthritis. Inhibition of VEGFR2 in vitro significantly blocked ICAM-1-dependent monocyte
adhesion to brain microvascular endothelial cells, when stimulated with inflammatory mediators TNF-
a and VEGF-A165a. Taken together our findings suggest that a novel VEGFR2-mediated spinal cord glio-
vascular mechanism may promote peripheral CD11b+ circulating cell transmigration into the CNS par-
enchyma and contribute to the development of chronic pain in inflammatory arthritis. We hypothesise
that preventing this glio-vascular activation and circulating cell translocation into the spinal cord could
be a new therapeutic strategy for pain caused by rheumatoid arthritis.
 2018 The Authors. Published by Elsevier Inc. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction varied forms (Walsh and McWilliams, 2012), and suffer from allo-Pain experienced by rheumatoid arthritis patients is chronic,
debilitating, and can persist despite adequate control of inflamma-
tion (Taylor et al., 2010; Heiberg and Kvien, 2002; McWilliams and
Walsh, 2016). The mechanisms that drive pain in rheumatoid
arthritis are complex and involve peripheral inflammation, joint
damage, peripheral nociceptive processes and central sensitization,
the latter being thought to underpin chronic pain. Because of this
complex aetiology, patients can experience unprovoked pain indynia (pain to innocuous stimuli) and hyperalgesia (heightened
sensation of painful stimuli) (Meeus et al., 2012; Wendler et al.,
2001). In addition, pain-associated psychological distress and fati-
gue further disrupt quality of life (Roche et al., 2003; Ulus et al.,
2011). Current therapies for rheumatoid arthritis aim to control
systemic and joint-associated inflammation and have a degree of
success (Walsh and McWilliams, 2012), but often fail to control
pain. There still remains, therefore, a pressing need for better con-
trol for the pain that persists in the face of optimal inflammatory
control (McWilliams and Walsh, 2016; Emery, 2012).
Chronic inflammatory diseases such as rheumatoid arthritis
are also associated with widespread endothelial ‘dysfunction’
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2014). The central nervous system (CNS) microvasculature, includ-
ing the spinal cord, is unlike microvasculature elsewhere in the
mammalian body, forming a more highly selective blood-brain/
spinal cord barrier (BBB/BSCB) which maintains neuronal home-
ostasis. The BBB/BSCB contains endothelial cells, vascular pericytes
(Graeber et al., 1990), astrocytic end-feet, and perivascular macro-
phages (Hickey and Kimura, 1988; Graeber et al., 1989). Astrocytic
end-feet ensheathe the microvasculature and regulate vessel func-
tion. For example, release of astrocytic endothelin-1 is vasocon-
strictive (Macrae et al., 1993) and astrocytic monocyte attractant
protein-1 promotes leukocyte migration across the human brain
endothelium, which can be blocked by inhibiting intercellular
adhesion molecule-1 (ICAM-1) (Weiss et al., 1998). More recent
research indicates microglial tumor necrosis factor-alpha (TNF-a)
stimulates glio-vascular activation, promoting endothelial prosta-
glandin I2 receptor expression and this mechanism contributes
to the generation of neuropathic pain (Kanda et al., 2017). In con-
trast to the CNS microvasculature the microvascular barrier in sen-
sory dorsal root ganglia (DRG) is fenestrated and less restrictive
(Abram et al., 2006; Anzil et al., 1976; Jacobs et al., 1976; Segond
von Banchet et al., 2009).
Immune cells (monocytes/macrophages, lymphocytes, neu-
trophils and mast cells), glia (astrocytes and microglia) and vascu-
lar endothelia can all contribute to the development of sensitized
pain pathways in both the CNS and the periphery [reviewed by
(Scholz and Woolf, 2007)]. Microglia are CNS innate immune cells
derived from proliferating residential microglia or circulating mye-
loid cells that transmigrate into the parenchyma (Hess et al., 2004;
Eglitis and Mezey, 1997; Lawson et al., 1992; Yao et al., 2016).
Stimulated microglia can release pro-nociceptive factors such as
TNF-a, interleukin-1b and interleukin-6 (Ledeboer et al., 2005;
Raghavendra et al., 2004; Ohtori et al., 1976). These promote
increased firing of neurons, enhancing information transfer
(Konig et al., 2016; Reeve et al., 2000), and in nociceptive systems
potentially contributing to a sensitized neuronal state (central sen-
sitization). Consequently, agents that inhibit microglial activity,
such as minocycline, have anti-nociceptive properties in preclinical
pain models (Ledeboer et al., 2005; Zhang et al., 2012; Chen et al.,
2013; Sagar et al., 2011).
Along with TNF-a, vascular endothelial growth factor-A (VEGF-
A) protein is increased in the serum of rheumatoid arthritis
patients (Nakahara et al., 2003). VEGF-A and TNF-a are co-
related (Nowak et al., 2008), with TNF-a driving endothelial
expression of both VEGF-A165a and endothelial adhesion molecules
(Haraldsen et al., 1996; Radisavljevic et al., 2000). Anti-TNF-a ther-
apy (e.g. etanercept) can significantly reduce VEGF-A levels in
rheumatoid arthritis (Strunk et al., 2006; Macias et al., 2005).
VEGF-A levels in patients that do not respond to anti-TNF therapy
can remain significantly elevated or even increase further
(Knudsen et al., 2009) indicating TNF-independent VEGF-A expres-
sion in non-responders and suggests an alternative therapeutic tar-
get. VEGF-A regulates blood vessel function including endothelial
activation through VEGF receptor-2 (VEGFR2): the pro-angiogenic
VEGF-A splice variant VEGF-A165a triggers endothelial expression
of chemokines and cell surface adhesion molecules including
ICAM-1 (Kim et al., 2001), and stimulates immune cell transmigra-
tion across brain endothelial cells (Lee et al., 2002). In addition
recombinant human (rh)VEGF-A165a (full receptor agonist) has
pro-nociceptive effects whereas the partial VEGF receptor agoinst
rhVEGF-A165b has opposing actions on nociception (Hulse et al.,
2014; Hulse et al., 2015). Targeting specifically VEGFR2 in normal
animals including by intrathecal inhibitor injection also signifi-
cantly affects rodent nociceptive behavior (Hulse et al., 2014;
Hulse et al., 2016).To date it is unclear how targeting VEGFR2 disrupts nociceptive
processes. With the knowledge that anti-VEGFR2 is anti-
nociceptive in preclinical models of neuropathic pain, we hypoth-
esized that targeting VEGFR2 would be anti-nociceptive in an
inflammatory mono-arthritis model. As leukocytes transmigrate
into the spinal cord parenchyma and dorsal root ganglia in other
preclinical pain models (Zhang et al., 2016; Zhang et al., 2007),
and VEGF-A is an endothelial ‘activator’ we also hypothesized that
spinal dorsal horn and dorsal root ganglion endothelia would be
activated in inflammatory arthritis. As a consequence to endothe-
lial activation, we hypothesised that targeting VEGFR2 would
reduce endothelial activation and the number of reactive spinal
cord microglia thereby providing a novel mechanism for the anti-
nociceptive effect of anti-VEGFR2 in vivo, and a novel target for
the treatment of chronic pain in inflammatory arthritis.2. Materials and methods
All animal procedures were performed in accordance with the
United Kingdom Animals (Scientific Procedures) Act 1986/Amend-
ment Regulations 2012 and with University of Nottingham Animal
Welfare and Ethical Review Group approval. Animals were main-
tained under 12 h/12 h light/dark-cycle, 21 ± 2 C with standard
chow and water ad libitum. A total of 70 male Wistar rats (Charles
River UK, 200–250 g starting weight) and 119 transgenic experi-
mental mice were used in this study.
2.1. Animal housing design, group randomization and sample size
Experimental group allocation was randomized per cage while
ensuring that in each cage there was amix of all groups tominimise
possible inter-cage interactions,with the exceptionof vehicle-dosed
vegfr2fl/fl Tie2CreERT2 mice: tamoxifen used for Tie2CreERT2 induc-
tion (see below) and its active metabolites are present in urine
(Kisanga et al., 2005). This excretion could lead to cross-
contamination between vehicle- and tamoxifen-dosed animals in
the same cage so these mice were housed separately. Rats (two-
tier cages) and mice (single-tier cages) were housed four and four-
to-six per cage in individually ventilated cages respectivefully. Ani-
mal welfare checks were performed daily throughout the experi-
ments. The primary measure was ipsilateral mechanical threshold
behavior therefore sample sizes were based on previous experi-
ments using these models (Chillingworth and Donaldson, 2003;
Hsieh et al., 2015; Kelly et al., 2007) and an unpublished pilot study.
2.2. Induction of articular inflammation
Complete Freund’s adjuvant (CFA) was prepared by resuspend-
ing heat-denatured mycobacterium tuberculosis [UK Ministry of
Agriculture Fisheries and Food, now known as DEFRA, UK] in min-
eral oil at 2 mg/mL, sonicated (1 h) and filtered (40 lm pore size).
Rats underwent unilateral intra-articular (tibiofemoral) injection
of 100 lg CFA (in 50 lL oil) under brief isoflurane anesthesia (2–
3% in oxygen). Non-injected control rats were age/sex-matched
and used to control for the inflammation. CFA vehicle was not
injected into control animals because the oil and joint damage
from the injection are sufficient to cause inflammation confound-
ing the interpretation of results. Transgenic mice underwent uni-
lateral sub-cutaneous, peri-articular (tibiotarsal) injection of CFA
[2  80 lg CFA in 40 lL oil, on either side of the joint
(Chillingworth and Donaldson, 2003) under isoflurane anesthesia
(2–3% in oxygen) two weeks after tamoxifen induction. Sham mice
underwent anesthesia and injection site preparation without CFA
injection. Thus this was a non-inflamed control group matching
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action of CFA alone.
2.3. Systemic antibody and pharmacological inhibitor administration
VEGFR2 signaling was targeted by i.p. injection of: 20 lg/kg
VEGF-A165b in PBS [VEGF receptor competitive antagonist
(Kawamura et al., 2008), anti-angiogenic VEGF-A isoform
(Woolard et al., 2004), received from K. Ballmer-Hoffer]; 15 mg/kg
PTK787 in PBS [VEGFR1/VEGFR2 inhibitor, vatalanib dihydrochlo-
ride, Selleckchem (Wood et al., 2000) with high BBB penetration
(Remko et al., 2011), or 12 lg/kg DC101 in PBS [neutralizing
murine-specific anti-VEGFR2 antibody (IgG mAb, BioXcell)]. To
control for off-target effects of DC101 immunoglobulin (IgG), con-
trol animals were given species/concentration-matched IgG (MP
Biomedicals, same route/vehicle). Intra-peritoneal inhibitor injec-
tion was performed immediately after intra-articular CFA and at
later time points (see results).
2.4. Local antibody and pharmacological inhibitor administration
VEGFR2 signaling was targeted in the right tibiofemoral joint by
intra-articular (local) injection on days 0 and 7 of VEGF-A165b [20 ng
injected with CFA (day 0) and in 50 lL PBS (day 7)] or PTK787
[100 pmol injected with CFA (day 0) and in 50 lL PBS (day 7)].
2.5. Measurement of nociceptive behaviors and joint swelling
All behavioral assays were conducted blinded to the experimen-
tal groups. Animals were habituated to operator handling and test-
ing environments over 3 days prior to testing. Animals were
allowed 20 min to re-acclimatize prior to testing. Mechanical
stimulus-withdrawals were recorded as previously described
(Hulse et al., 2014): von Frey monofilaments (mouse: 0.04–2 g;
rat: 0.16–26 g) were applied five times to each hind paw, for
5 s and the percentage of response scored. The 50% withdrawal
threshold was calculated from the stimulus–response relationship
[generated by plotting percentage of response against the loga-
rithm (base 10) of applied force] using Graphpad Prism 7. Ipsilat-
eral and contralateral (to CFA injection) hind limb weight
distribution was measured using an incapacitance tester (Linton
Instrumentation, UK). The weight borne by each hind limb was
averaged over 3 s and the mean of three readings calculated.
Results are displayed as ipsilateral hind limb weight bearing as a
percentage of total weight borne on the hind limbs. Tibiofemoral
joint diameter in awake rats and tibiotarsal joint diameter in
awake mice were recorded using a digital caliper. Readings were
taken in triplicate and mean values calculated.
2.6. Spinal cord and DRG immunofluorescence
Eight and 11 days after induction of articular inflammation
rats were terminally anesthetized with sodium pentobarbital
(60 mg/ml) and perfuse-fixed with 250 mL ice cold PBS + heparin
(1U/mL) followed by 250 mL ice cold 4% paraformaldehyde (PFA)
in PBS. Tissue was collected at these time points as significant sec-
ondary allodynia had developed in these rats and changes in pain
behavior with treatment were observed on the preceding days
(days 7 and 10). The study design did not permit the full suite of
behaviour measurements and tissue collection on the same day.
In our experience of this model secondary mechanical allodynia
peaks after one week (Drake et al., 2016) and is maintained to at
least day 14 therefore we selected time points for tissue analysis
when secondary pain was established. Mouse spinal cords were
perfuse-fixed as above and dissected following the completion of
the behavioral tests on day 14, a time point at which significantdifferences in contralateral behavior were observed. Spinal col-
umns were placed into PFA overnight, then into 30% sucrose in
PBS for upto 72 h. Spinal cord lumbar enlargement (central site
corresponding to hind paw sensory input and site of secondary
sensitivity, L4-L5 (Butler and Comparative, 2005)and ipsi- and con-
tralateral lumbar dorsal root ganglia (ganglia corresponding to the
majority of sensory input from knee, L3 (Russell et al., 2012)were
dissected and frozen in optimal cutting temperature (OCT)
compound (VWR, UK) on dry ice. Spinal cord (20 lm) and DRG
(20 lm) cryosections were cut and thaw-mounted onto slides
(SuperFrost Plus, VWR). Sections were rehydrated in PBS + 0.2%
Triton X-100 (PBS-X) and blocked (10% fetal bovine serum, 5%
bovine serum albumin in PBS-X) for 2 h at room temperature.
Due to the thickness of the sections, primary antibodies in blocking
solution were incubated overnight at 4 C and slides were washed
with PBS-X (3, 10 min). Slides were incubated overnight with
secondary antibodies in blocking solution (4C, humid conditions)
and washed as above. Finally slides were incubated with strepta-
vidin for 2 h at room temperature, washed as above and mounted
in Fluoroshield. Primary antibodies: glial fibrillary acid protein
(GFAP) (Abcam, ab7260, pAb anti-serum) used at 1 in 500;
CD11b (microglial/monocyte marker) (BioRad, MCA275) used at
0.2 lg/mL; ICAM-1 (activated endothelial cell marker) (Abcam,
ab171123) used at 0.2 lg/mL; IB4 (Sigma, L3759) used at
1 lg/mL; VEGFR2 (Cell Signaling, 55B11) used at 1 in 250, CD31
used at 5 lg/mL (R&D Systems, AF3628). Secondary antibodies
(goat anti-mouse/rabbit, Alexa Fluor-conjugated, Life Technolo-
gies) all used at 1 in 1000; streptavidin-488 (Life Technologies)
used at 1 in 500, Hoechst543334 used at 1 lg/mL.
2.7. Confocal microscopy and analysis
Fluorescence images were captured using Leica SPE confocal
microscope using 10, 40 and 63 oil immersion objective
lenses and Leica Applications Suite software (LAS X). ImageJ soft-
ware was used for image analysis. CD11b+/Hoechst total dorsal
horn cell counts were automated using ImageJ: the dorsal horn
(laminae I-V) was traced, then CD11b+ and Hoechst 1024x1024
resolution 8-bit images were thresholded with consistent settings
across all groups, and the percentage of overlay determined using
the particle analyzer and measure functions. Nuclei overlayed by
>35% of the CD11b+ signal were deemed CD11b+ cells. This per-
centage was optimized to match manual counts from pilot manual
analysis. Dorsal horn GFAP, CD11b or ICAM-1 immunofluorescent
signal was manually quantified as being vessel-associated if the
signal localized with a vessel. In the rat study a GFAP, CD11b or
ICAM-1-associated vessel was identified if the fluorescent signal
localised with nuclear staining indicative of vessels: longitudinal/
oblique vessels were identified by a chain of two or more elongated
flat nuclei (endothelial cells or pericytes, dotted elipses, Fig. 1h,i,l)
and cross-sectional dorsal horn vessels were identified by two or
more curved nuclei forming a crescent or complete ring (endothe-
lial cells or pericytes dotted elipses, Fig. 1f,i). In the Tie2-CreERT2
VEGFR2 KO study the vessel localization was aided with CD31
co-staining. All manual ICAM-1+, CD11b+ and GFAP+ vessel analy-
ses were performed with the analyser blinded to experimental
group. The number of ICAM-1+, CD11b+ or GFAP+-associated vessel
fragments per animal were counted and expressed over the total
sectional area per animal analysed to account for differences in
the total area analysed.2.8. Generation of Tie2-CreERT2 x vegfr2fl/fl mice
To elucidate the site of action of the anti-VEGFR2 agents we
crossed mice that were homozygous for the VEGFR2 gene with
floxP sites either side of exon 1 (vegfr2fl/fl) (Albuquerque et al.,
52 N. Beazley-Long et al. / Brain, Behavior, and Immunity 74 (2018) 49–672009) with Tie2CreERT2 mice [European Mutant Mouse Archive
EM:00715 (Forde et al., 2002) to generate inducible endothelial
vegfr2 knock-out adult mice. Experiments were conducted onM
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Tamoxifen (Sigma, T5648) was dissolved in ethanol then
diluted 1 in 10 in autoclaved sunflower oil (vehicle 10% ethanol,
90% oil) (Acharya et al., 2011). Five daily doses of tamoxifen (1 m
g/100 lL i.p.) or vehicle (volume/route-matched) were adminis-
tered to either Tie2CreERT2-positive or Tie2CreERT2-negative mice
as a control for actions of tamoxifen.2.10. CD31+ cell selection for endothelial cell knock-out
characterisation
Two to four weeks after tamoxifen/vehicle induction, mice were
transcardially perfused (20 mL PBS + heparin 10U/mL), 100 mg
lung or spinal cord tissue dissected, washed twice with PBS and
enzymatically (0.125% collagenase P, 1 h, 37 C) and mechanically
dissociated (triturated with P1000 micropipette), cell dispersate
passed through a 40 lm cell filter and entered into a mouse
CD31+ selection microbead assay (20 million cells) using MS
columns and following the manufacturer’s instructions
(Miltenyibiotech).2.11. VEGFR2 genomic DNA and mRNA characterisation
Following CD31-positive cell selection genomic DNA (Qiagen,
DNeasy kit) and RNA (Chomczynski and Sacchi, 1987) (CD31-
positive, column flow-through and input fractions) were extracted
and purified. Genomic DNA (100 ng) was amplified by conven-
tional PCR with 1 forward primer (F) and 2 reverse primers (R1,
R2) designed to detect wild-type vegfr2 gene (F-R1, 322 bp) and/
or loxP-flanked vegfr2 gene (F1-R3, not knocked out 439 bp, or
knock-out product 218 bp) as performed previously
(Albuquerque et al., 2009; Sison et al., 2010) with annealing tem-
perature 65 C, primers: F; 5 -CTTTCCACTCCTGCCTACCTAG-3; R1,
5–TGGAGAGCAAGGCGC-TGCTAGC-3; R2, 5 -AATTTGGGTGCCATA
GCCAATC-3). To investigate changes in VEGFR2 mRNA by RT-PCR
500 lg RNA was treated with DNaseI and reversed transcribed
with 500 ng Oligo-d(T) and 250 ng random primers and M-MLV
reverse transcriptase (all Promega). 1 lL of the total 20 lL
complementary DNA (cDNA) was added to 2.5 lL Taqman
probe +9 lL ddH2O +12.5 lL ddPCR Supermix for probes (Bio-
Rad). Droplets were generated by adding the 25 lL to 70 lL Dro-
plet oil (Bio-Rad) using a QX100 droplet generator (Bio-Rad).
Amplification of VEGFR2 or CD31 cDNA was carried out using
standard Taqman protocols (10 min activation step 95 C, 40 cycles
of 30 s denaturation at 94 C, 1 min annealing at 60 C and final
10 min extension at 98 C using a PCR thermal cycle (Bio-Rad)
with VEGFR2 (KDR, Mm01222421_m1) and PECAM1 (CD31,
mM01242584_mi) Taqman Primers (Life Technologies). Samples
were analysed using a QX100 droplet reader (Bio-Rad). Threshold-
ing was manually performed, based on negative and positive
control results only when automatic thresholding of values was
not possible.Fig. 1. Articular inflammation drives secondary mechanical allodynia, glio-vascular act
weight borne on the ipsilateral hind paw (b), ipsilateral mechanical stimulus withdrawal
intra-articular CFA (single dose, 100 lg), n = 9 (CFA), n = 4 (non-inflamed controls). Im
following induction of inflammatory arthritis (e-l). Representative images (e,g,k) showing
in (e-f) non-inflamed control, (g-j) day eight and (k-l) day 11 following induction of ar
microvessels, identified by strings of flat (longitudinal) or curved (cross-sectional) nucle
with CD11b+ cells (green, arrows) at day eight (h,i). 2D image following z-stack reconstr
Wide spread dorsal horn CD11b+ microglia-like staining within the dorsal horn parenchy
horn of non-inflamed controls (m-r) and CFA-treated animals on day 8 (n) and 11 (m). ICA
immunoreactivity was associated with CD31+ vessels (q) and vessels wrapped in GFAP+
variance + Dunnett’s multiple comparisons test. CFA + vehicle vs. respective baseline:
interpretation of the references to colour in this figure legend, the reader is referred to
32.12. VEGFR2/Tie2 flow cytometry
Following CD31+ lung or spinal cord cell selection, cells were
incubated with calceinAM (2.5 lM, 200, 37 C), then stained with
fluorophore-labeled antibodies against mouse Tie2 (PE-
conjugated, Biolegend #124008, 10 lg/mL) and mouse VEGFR2
(APC-conjugated, Biolegend #136406, 10 lg/mL), and total nuclei
stained with Hoechst543334. Flow cytometry was performed
(MoFlo Astrio Cell Sorter) to determine changes in proportions of
living Tie2+ and VEGFR2+ cells. Single dye control groups identified
that no signal compensations were required between the four dyes
(Hoechst543334: 350–488/59 nm, Calcein: 488–513/26 nm, PE:
561–579/16 nm, APC: 640–671/30 nm). In samples from lung, side
and forward scatter of calcein-positive (living) cells revealed two
distinct populations, a low Tie2/VEGFR2-negative population and
a high Tie2/VEGFR2 population. Changes in Tie2 and VEGFR2
expression in these two populations were investigated between
tamoxifen-induced and uninduced (vehicle-treated) mice. In sam-
ples from spinal cord, distinct populations of living cells were not
evident when analysed by side and forward scatter properties so
all living CD31+ cells were analysed for Tie2 and VEGFR2
expression.
2.13. Human brain endothelial cell – Monocyte adhesion assay
Human brain microvascular endothelial cells (HBMEC) were
cultured in RPMI + 20% FBS, 2 mM L-glutamine, 1 mM sodium
pyruvate, 1% MEM non-essential amino acids, 1% MEM vitamin,
1% penicillin/streptomycin. Human monocytes (THP-1, Sigma)
were cultured in RPMI + 10% FBS, 1% penicillin/streptomycin.
HBMECwere plated in 96 well plates at 30,000 cells/well and treat-
ments were performed in RPMI + 1% FBS, 1% penicillin/strepto-
mycin. Endothelial monolayers were pretreated overnight with
either VEGF-A165b, ZM323881 (20 nM) or PTK787 (100 nM) prior
to 24 h treatment with recombinant human TNF-a (R&D Systems).
A blocking ICAM-1 antibody (100 ng/mL) or a concentration and
species-matched IgG (100 ng/mL, ms IgG) was added with TNF-a
treatment and again at the time of monocyte addition. Monocytes
were fluorescently tagged with 2.5 lM calcein-AM for 1 h at 37 C,
washed in warm PBS, added to HMBEC monolayer at 30,000 cells
per well and incubated for 2 h for attachment. Unattached mono-
cytes were washed off and cells fixed with 4% PFA. Calcein fluores-
cence was measured on fluorescence plate reader (VictorX4,
Perkin-Elmer). Results shown have had the mean fluorescence
value of the untreated group (without stimulation) subtracted
and then are expressed as a percentage of the mean fluorescence
of the maximal response.
2.14. Western blotting
HBMEC and human umbilical vein microvascular cell (HUVEC)
protein lysate was prepared from  80% confluent cultured cells
in RIPA lysis buffer with protease inhibitor cocktail (P8340, Sigma).
Samples (10 lg) were separated by SDS-PAGE on a 4–20% gradientivation and microglia reactivity in the spinal cord. Tibiofemoral joint diameter (a),
threshold (c) and contralateral mechanical stimulus (d) withdrawal threshold after
munoreactivity of GFAP and CD11b antibodies in the dorsal horn 8 and 11 days
the increase in GFAP (red) and CD11b (green) immunoreactivity in the dorsal horn
ticular inflammation with CFA (nuclei- blue). High magnification imaging revealed
i (blue), surrounded by GFAP+ astrocytic end-feet (red, arrowhead) and associated
uction showing a CD11b+ cell with a cellular projection within the vessel lumen (j).
ma by day 11 (k-l). Representative images showing ICAM-1 expression in the dorsal
M-1+ microvessel fragments (p) were observed throughout the dorsal horn. ICAM-1+
astrocytic end-feet (r). Statistical analysis: two-way repeated measures analysis of
***p,<0.001, ****p < 0.0001. Group size = 8–9. Data displayed as mean ± SD. (For
the web version of this article.)
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transferred onto nitrocellulose membrane by turbo transfer (Bio-
Rad TransBlot Turbo, 25 V for 7 min). Membranes were incubated
with either a-occludin (71–1500, rabbit, 0.5 mg/mL), a-von Wille-
brand Factor (ab6994, rabbit, 17 lg/mL) or a-actin (sc1615, goat,
0.5ug/ml was used as a loading control). Secondary antibodies used
were IRDye 680RD donkey anti-rabbit IgG, IRDye 800CW donkey
anti-mouse or IRDye 800CW donkey anti-Goat IgG, all at
0.2 mg/mL and membranes visualized on LiCor Odyssey Fc.2.15. Data extraction and statistical analysis
Acquired data were processed and graphed using GraphPad
Prism v6. All data were Gaussian distributed and are shown as m
ean ± standard deviation. For statistical comparisons each animal
was an experimental unit. Three or more groups were compared
using one- or two-way analysis of variance with post-hoc Dunnett’s
multiple comparisons tests to test for significant differences to the
respective control group. Spearman correlation analysis was per-
formed to test for significant correlation between mechanical
threshold scores and histological data.3. Results
3.1. Intra-articular complete Freund’s adjuvant drives dorsal horn
astrocytic, microglial and microvascular reactivity
We first investigated pain behavior and the reactivity of dorsal
horn microglia, astrocytes and microvessels in response to intra-
articular CFA. CFA caused a significant increase in tibiofemoral
diameter Fig. 1a), a significant decrease in weight borne on the
ipsilateral hind paw Fig. 1b) and a significant decrease in the ipsi-
lateral hind paw mechanical threshold Fig. 1c). The contralateral
hind paw mechanical threshold decreased by day 10 to 65% of
baseline indicating sensiziation but this did not reach statistical
significance compared with respective baseline (p = 0.056) nor
compared with non-inflamed controls (p = 0.071), when analysed
by 2-way ANOVA + post hoc analysis Fig. 1d). The significant
decrease in ipsilateral hind paw mechanical threshold (secondary
mechanical allodynia) indicated the development of central sensi-
tization. In many chronic painful diseases and animal models reac-
tive astrocytes and microglia in the dorsal horn contribute to
central sensitization and the generation of pain (Taylor et al.,
2017; Mifflin and Kerr, 2017), therefore we investigated changes
in dorsal horn glial fibrillary acidic protein (GFAP, reactive astro-
cytes) and CD11b (reactive microglia) expression at the spinal level
corresponding to sensory input from the site of secondary sensitiv-
ity (sensitized hind paw, L5). Eight days after intra-articular CFA,
GFAP expression was more prominent (red, denoted by arrow-
heads, Fig. 1 h,i,j) than in non-inflamed controls Fig. 1e-f), and
there was a small number of CD11b+ cells (green, denoted by
arrows, Fig. 1 g-j), which were not observed in non-inflamed con-
trols. At this time point a proportion of GFAP immunoreactivity
and the majority of observed CD11b+ cells were associated with
nuclear staining indicative of microvessels Fig. 1 h-j), and image
reconstruction demonstrated that the GFAP+ processes (reactive
astrocytic end-feet) were wrapped round vessel-like structures in
which CD11b+ cells were present (highlighted in Fig. 1i,j). For illus-
trative purposes nuclear staining indicative of microvessels is
encircled by dashed ellipses in high magnification images Fig. 1f,
h,i,j,l). At day 11 GFAP imunoreactivity was associated with
microvessels while CD11b+ cells were widespread throughout the
dorsal horn parenchyma Fig. 1 k,l). The number of GFAP+ reactive
astrocytic end-feet associated with microvessel nuclear staining
in the ipsilateral dorsal horn increased from 0.41 ± 0.07  105lm2 (non-inflamed) to 1.35 ± 0.09  105 lm2 (day 8) and 1.0
2 ± 0.22  105 lm2 (day 11). At day 11, CD11b+ microglia-like
cells were widespread in the dorsal horn parenchyma Fig. 1 k,l)
and had increased from 0.05% ± 0.09 (non-inflamed) to 8.93% ± 1.
17 (% of total cells).
CD11b is a natural ligand for ICAM-1 (Springer, 1990), a key
molecule in the adhesion and extravasation of leukocytes through
activated vascular endothelium following spinal cord injury
(Isaksson et al., 1999). Increased ICAM-1 expression in dorsal
horn-activated endothelium as a result of peripheral inflammation
could contribute to transendothelial migration of CD11b+ cells into
the CNS parenchyma. Compared with non-inflamed animals
Fig. 1m) there was indeed a significant increase in the number of
ICAM-1+ vessels throughout the dorsal horn of CFA animals at days
eight and 11 (green elongate structures associated with microves-
sel nuclear staining, Fig. 1n-p), (non-inflamed 0.22 ± 0.22  10-5
lm-2, day 8 11.67 ± 0.10  10-5 lm-2, day 11 11.64 ± 02.07  10-5
lm-2). ICAM-1 and CD31 co-staining confirmed ICAM-1+ microves-
sels in the dorsal horn of CFA-treated animals Fig. 1q). GFAP (red)
and ICAM-1 (green) co-staining also identified ICAM-1+ microves-
sels associated with GFAP+ astrocytic end-feet Fig. 1r) in the dorsal
horn of CFA animals.
3.2. Intra-peritoneal but not intra-articular delivery of anti-VEGFR2
agents is anti-nociceptive in inflammatory arthritis
The spinal endothelial activation suggested that reducing cen-
tral endothelial activation could be a route to preventing
vascular-associated detrimental changes within the CNS. As
VEGF-A has been shown to induce ICAM-1 through VEGFR2 (Usui
et al., 2004) and we have previously found that VEGF-A is involved
in pain states (Hulse et al., 2014; Hulse et al., 2015; Hulse et al.,
2016), we sought to investigate whether inhibiting VEGFR2 by sys-
temic delivery of anti-VEGFR2 agents affects the development of
pain-associated behaviors through central rather than peripheral
actions. To target VEGFR2 we used a naturally occurring VEGFR2
partial agonist, VEGF-A165b (Kawamura et al., 2008) that inhibits
vascular action (Ourradi et al., 2017) and has anti-nociceptive
properties (Hulse et al., 2014, 2015), a small molecule VEGFR1&2
inhibitor with high BBB penetration, PTK787 (Remko et al., 2011)
that also has anti-nociceptive properties (Hulse et al., 2014,
2015) and a murine-specific VEGFR2 neutralising antibody that
would not freely cross the BBB, DC101. Two systemic doses (days
0 and 3) of either VEGF-A165b (20 lg/kg i.p., Fig. 2), PTK787 (15
mg/kg i.p., Fig. 2) or DC101 (12 mg/kg i.p., Fig. 2) did not signifi-
cantly affect the joint diameter compared to control Fig. 2a). The
VEGFR2 neutralising antibody DC101 and VEGF-A165b both had a
significant inhibitory effect on the shift in weight bearing by day
10 Fig. 2b). All three anti-VEGFR2 treatments significantly inhib-
ited the development of secondary mechanical allodynia in the
ipsilateral hind paw compared CFA + control on day 7 Fig. 2c).
CFA induced a drop in contralateral hind paw threshold in control
animals although this did not reach significance from respective
baseline. However on day 10 both VEGF-A165b and DC101 treat-
ments caused a signficant increase in weight borne on the ipsilat-
eral paw compared to day 10 control animals Fig. 2d). In contrast to
systemic delivery, intra-articular anti-VEGF agents (VEGF-A165b or
PTK787) did not affect the development of secondary mechanical
allodynia in the ipsilateral hind paw Fig. 3a,d), the shift in hind
paw weight bearing to the contralateral side Fig. 3b,e), nor joint
swelling Fig. 3c,e). These results indicate that systemic inhibition
of VEGFR2 signalling, but not local inhibition in the knee, is anti-
nociceptive, suggesting a mechanism that is distinct from the inhi-
bition of local VEGF-A receptors in the joint. Furthermore, the
effects on mechanical allodynia of all three systemically adminis-
tered anti-VEGF agents, including a specific VEGFR2-neutralizing
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Fig. 2. Systemic delivery of anti-VEGFR2 agents prevents the development of secondary mechanical allodynia. Tibiofmoral joint diameter after intra-articular CFA + two i.p.
injections (arrows) of either a murine VEGFR2-specific neutralising antibody (DC101), VEGF-A165b or PTK787 compared with control (Control IgG) (a). Weight bearing on the
paw ipsilateral to CFA injection after treatment with either DC101 (murine neutralizing VEGFR2 mAb), PTK787 (VEGFR1&2 inhibitor) or VEGF-A165b (competitive VEGF
receptor antagonist) (b). Ipsilateral hind paw mechanical sensitivity after CFA and VEGFR2 inhibition (c). Contralateral hind paw sensitivity (d). Two statistical analyses were
performed: two-way repeated measures analysis of variance + Dunnett’s multiple comparisons tests: CFA + Control IgG vs. respective baseline, *p < 0.05, **p,<0.01, ***p <
0.0001; or CFA + drug vs. CFA + Control IgG at given time point, ]p < 0.05; ]]p < 0.01, ]]]p < 0.0001, ]]]]p < 0.0001. Group size = 5–9. Data displayed as mean ± SD.
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effect of DC101, which would not freely cross into the CNS par-
enchyma, indicates a possible site of inhibition within the vascula-
ture itself.
3.3. The effect of anti-VEGFR2 agents on glia reactivity in the dorsal
horn of the spinal cord
As anti-VEGFR2 agents supressed secondary pain behavior
when administered systemically rather than locally, we investi-
gated changes in CFA-induced reactive glia and microvessels in
the dorsal horn after anti-VEGFR2 treatment. The number of
GFAP-wrapped vessel-like structures was enhanced in both ipsilat-
eral and contralateral dorsal horn in the CFA + control group at
both day eight Fig. 4a-d,i) and day 11 Fig. 4e-h,j), and only
DC101 treatment significantly affected the number of GFAP-
wrapped vessels (ipsilateral, day 8). As observed in Fig. 1(g-j), a
small, non-significant number of CD11b+ cells were detected in
the dorsal horn parenchyma after 8 days compared with non-
inflamed control animals Fig. 4a-d,k; Fig. 1i,j). However, of those
that were detected, a significant number (CD11b+ cells, arrows
Fig. 4a-d) were detected in association with the dorsal horn
microvasculature of all CFA groups, suggesting an upregulation of
CD11b+ cells in the microcirculation associated with peripheral
inflammation Fig. 4a-d,l). By eleven days after intra-articular CFA
there was a significantly increased number of CD11b+ cells within
both the ipsi- and contralateral dorsal horn parenchyma of CFA-treated animals Fig. 4e-h,m). All VEGF inhibitory treatments
reduced the number of CD11b+ cells in the spinal cord parenchyma
on day 11, but this reached significance only for VEGF-A165b and
PTK787. A significant number of these CD11b+ cells were associ-
ated with the microvasculature compared to non-inflamed control
and compared to the number on each respective day eight with no
observed difference between all CFA groups Fig. 4e-h,n). This sug-
gested that the treatments had reduced the migration of CD11b+
cells from blood vessels into the surrounding parenchyma. The sig-
nificant increase in dorsal horn CD11b+ cell number on day 11 sig-
nificantly and negatively correlated with ipsilateral hind paw
mechanical threshold (Supplementary Fig. S1). No differences were
observed between ipsi- and contralateral sides within each group
except in the VEGF-A165b group (number of GFAP-wrapped vessels,
day 11, Fig. 4j).
3.4. The effect of anti-VEGFR2 agents on dorsal horn vascular ICAM-1
expression
Inhibiting VEGF-A can inhibit ICAM-1 expression and monocyte
adhesion in vitro (Radisavljevic et al., 2000; Thichanpiang et al.,
2014). CD11b+ cells were initially associated with microvessels
(day eight) and were later located in the dorsal horn parenchyma
(day 11). We therefore tested the hypothesis that peripheral
inflammation caused an increase in dorsal horn endothelial
ICAM-1 expression which could underpin the possible
transendothelial migration of CD11b+ cells into the parenchyma.
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Fig. 3. Intra-articular (tibiofemoral) delivery of VEGF receptor inhibitors did not affect the development of pain-associated behaviors in the CFA model of inflammatory
monoarthritis. Intra-articular (i.a) CFA (single dose) plus two i.a. vehicle injections (arrow heads) caused a significant reduction in ipsilateral mechanical stimulus withdrawal
threshold (a,d) at all time points measured, weight borne on ipsilateral hind paw (b,e) (days 1–10) and a significant increase in tibiofemoral joint diameter (c,f) compared to
respective baseline (day 0). CFA + two i.a. injections of VEGF-A165b or PTK787 (arrow heads) had no effect on the development of the pain-associated behaviors and joint
diameter (a-f). Two statistical analyses were performed: 2-way ANOVA + Dunnett’s multiple comparisons tests: CFA + vehicle vs. respective baseline, *p < 0.05, **p < 0.01,
***p < 0.0001; or CFA + vehicle vs. CFA + drug, #p < 0.05, ##p < 0.01, ###p < 0.0001. A-C n = 10, D-F n = 5. Data displayed as mean ± SD.
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animals were present throughout the dorsal horn after 8 days
Fig. 5a), whereas fewer were seen in DC101, VEGF-A165b or
PTK787-treated groups at day eight Fig. 5b-d) but not at day 11
Fig. 5e-h). Quantification of the number of ICAM+ vessels showed
that CFA induced a significant increase on both sides of the spinal
cord at day eight, which was significantly reduced by DC101,
VEGF-A165b or PTK787 Fig. 5i). While the ICAM-1 induction was
still evident at day 11 Fig. 5j), VEGFR inhibition had no effect at this
time point. There were no differences between the ipsi- and con-
tralateral sides within each group except in the DC101 group
(day 8, Fig. 5i). The significant inhibition of ICAM-1+ microvessels
by anti-VEGFR2 treatment at day 8 may have reduced CD11b+
microglia-like cell transmigration into the parenchyma Fig. 4 m).3.5. The effect of VEGFR2 inhibitory agents on dorsal root ganglion
vascular ICAM-1 expression
Infiltration of inflammatory cells into DRG contributes to
chemotherapy-induced pain (Zhang et al., 2016), diabetic neuropa-thy (Rahman et al., 2016), and traumatic nerve injury (Austin et al.,
2015). ICAM-1/VEGFR2 double staining demonstrated that both
molecules were expressed in DRG of animals with CFA monoarthri-
tis Fig. 6a). ICAM-1 staining was noticeably more frequent in ipsi-
lateral DRG from CFA-induced animals Fig. 6b,c) and this was less
so with DC101 Fig. 6d), VEGF-A165b Fig. 6e) and PTK708 Fig. 6f)
treatment. There was a significant increase in the number of
ICAM-1+ vessels in ipsilateral, but not contralateral L3 DRG com-
pared to non-inflamed control after eight Fig. 6i) and 11 days
Fig. 6j). All three VEGFR2 inhibitory treatments significantly
decreased the number of ICAM-1+ vessels at both eight and 11 days
Fig. 6 g,h). No macrophages (CD68+ cells) were observed in the DRG
on day eight in any group (data not shown).3.6. Targeting VEGFR2 in cultured human brain microvascular
endothelial cells in a fluorescent monocyte adhesion assay
VEGF-A165a and TNF-a upregulate ICAM-1 expression through
activation of VEGFR2 in endothelial cells (Radisavljevic et al., 2000;
Hirano et al., 2017), retinal pigmented epithelial cells
05
10
15
20
25
C
D
11
b-
po
si
tiv
e 
ce
lls
 a
ss
oc
ia
te
d 
w
ith
 v
es
se
ls
 (n
o.
μm
-2
 x
10
-6
)
Ipsilateral
Contralateral
0
2
4
6
8
10
12
C
D
11
b-
po
si
tiv
e 
ce
lls
 
(%
 o
f t
ot
al
 d
os
al
 h
or
n 
ce
lls
)
Ipsilateral
Contralateral
0
5
10
15
20
25
C
D
11
b-
po
si
tiv
e 
ce
lls
 a
ss
oc
ia
te
d 
w
ith
 v
es
se
ls
 (n
o.
 ×
10
-6
μm
-2
) IpsilateralContralateral
0
2
4
6
8
10
12
C
D
11
b-
po
si
tiv
e 
ce
lls
 
(%
 o
f t
ot
al
 d
or
sa
l h
or
n 
ce
lls
)
Ipsilateral
Contralateral
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
G
FA
P-
w
ra
pp
ed
 v
es
se
l f
ra
gm
en
ts
 
(n
o.
 ×
10
-5
μm
-2
)
Ipsilateral
Contralateral
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
G
FA
P-
w
ra
pp
ed
 v
es
se
l f
ra
gm
en
ts
 
(n
o.
 ×
10
-5
μm
-2
 )
Ipsilateral
Contralateral
Fig. 4. The effect of anti-VEGFR2 agents on astrocytic and microglial reactivity to articular inflammation. Intra-articular CFA caused a significant increase in the number of
GFAP+ end-feet-wrapped vessel fragments in the ipsilateral dorsal horn on both (a) day eight and (e) day 11. Treatment with DC101 (b,f), but not VEGF-A165b (c,g) nor PTK787
(d,h) significantly reduced the number of ipsilateral and contralateral GFAP+ end-feet-wrapped vessel fragments on day eight (i), but not on day 11 (j). Intra-articular CFA
caused a significant increase in microvessel-associated CD11b+ cells (ipsi- and contralateral) on day eight (k) and day 11 (l) with no difference observed between the CFA
groups at both time points. On day eight there was no significant difference in the number of CD11b+ cells in the dorsal horn parenchyma compared to control (m), whereas
on day 11 there was a significant increase in CD11b+ cells in the dorsal horn parenchyma compared to non-inflamed control animals. All three anti-VEGF treatments reduced
this number although only VEGF-A165b (ipsi & contalateral) and PTK787 (ipsilateral) reached statistical significance (n). The only significant difference between respective
ipsi- and contralateral effects was observed in VEGF-A165b group on the number of GFAP-wrapped vessels at day 11 (j). Three statistical analyses were performed: 2-way
analysis of variance + Dunnett’s multiple comparisons test: control vs. non-inflamed *p < 0.5, **p < 0.01, ***p < 0.001, ****p < 0.0001; anti-VEGFR2 agent vs. control (ipsi or
contra): #p < 0.5, ##p < 0.01, ###p < 0.001, ####p < 0.0001 and ipsi vs. contra of respective group +p < 0.5. Day eight: n = 4; day 11: n = 4–5. Data displayed as mean ± SD.
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Fig. 5. The effect of anti-VEGFR2 agents on dorsal horn vascular activation. Representative low magnification images of ICAM-1 immunoreactivity in the dorsal horn (a-h).
Number of ICAM-1+ microvessels present in the dorsal horn (i,j). Three statistical analyses were performed: 2-way analysis of variance + Dunnett’s multiple comparisons test:
control vs. non-inflamed *p < 0.5, **p < 0.01, ***p < 0.001, ****p < 0.0001; anti-VEGFR2 agent vs. control (ipsi or contra): #p < 0.5, ##p < 0.01, ###p < 0.001, ####p < 0.0001
and ipsi vs. contra of respective group +p < 0.5. Day eight: n = 4; day 11: n = 4–5. Data displayed as mean ± SD.
58 N. Beazley-Long et al. / Brain, Behavior, and Immunity 74 (2018) 49–67(Thichanpiang et al., 2014; Lee et al., 2015), and rheumatoid arthritis
synoviocytes (Hulse et al., 2015; Lindsley et al., 1993). To test the
hypothesis that effects on ICAM-1 upregulation and monocyte
attachment were attributable to a possible direct action of VEGFR2
inhibitory agents on CNS endothelium we used human brain
microvascular endothelial cell (HBMEC)monolayers. An endothelial
phenotype was confirmed in HBMEC by immunoblot for vonWille-
brand factor (vWF, Fig. 7a, HUVEC-positive control). These cells also
expressed occludin, indicating the formation of tight junctions. Cells
treated with increasing concentrations of TNF-a showed that fluo-
rescently labeled monocyte (THP-1) attachment to HBMEC mono-
layers was significantly induced by TNF-a treatment and this was
significantly reducedbyco-treatmentwithan ICAM-1blockinganti-bodyFig. 7b). TreatmentwithVEGF-A165a (24 h) also caused a signif-
icant increase in fluorescence THP-1 monocyte attachment Fig. 7c),
and VEGF-A165b pre-treatment significantly inhibited this attach-
ment Fig. 7c). Pre- andco-treatmentwitha specificVEGFR2 inhibitor
(20 nMZM323881, Fig. 7d,e) or PTK787 (100 nM, Fig. 7d) also signif-
icantly inhibited VEGF-A165a-induced THP-1 monocyte attachment
to HBMEC, as did the addition of an ICAM-1 blocking antibody
Fig. 7c). In a similar manner to VEGF-A165a, TNF-a treatment (24 h)
caused an increase in attached THP-1 monocyte fluorescence
Fig. 7d) that could be blocked with VEGF-A165b, anti-VEGFR2 com-
pounds or blocking ICAM-1 antibody Fig. 7d). Thus TNF-a-
mediated THP-1monocyte adherence to endothelial cells from cen-
tral nervous tissue appears to be VEGFR2-dependent.
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Fig. 6. VEGFR2 inhibition reduces ICAM-1 expression in DRG. ICAM-1 and VEGFR2 immunoreactivity in the ipsilateral L3 dorsal root ganglion eight days following induction of
inflammatory arthritis (a). ICAM-1expressionwas localized toDRGmicrovessels expressingVEGFR2 (scale bar- 10 lm). Representative images showing ICAM-1expression in L3
DRG 8 days following induction of inflammatory arthritis with treatment with control IgG, DC101, VEGF-A165b or PTK787 (b-f). Arrow indicates ICAM-1+ vessel fragment. No
primary and species- and concentration-matched isotype control IgG staining (g,h). Scale bar-100 lm. Quantification of microvessel ICAM-1 expression in ipsilateral and
contralateral L3DRG fromnon-inflamed, or CFA injected animals onday eight (i) and11 (j) andwith anti-VEGF treatments. Statistical analyses: g,h: one-way analysis of variance
+ Dunnett’s multiple comparisons test: vs. non-inflamed *p < 0.5, **p < 0.01, ***p < 0.001, ****p < 0.0001; vs. CFA + IgG control: #p < 0.5, ##p < 0.01, ###p < 0.001, ####p <
0.0001 and ipsi vs. contra of respective group +p < 0.05, ++p < 0.01, +++p < 0.001, ++++p < 0.0001. Day eight: n = 3–4; day 11: n = 4–5. Data displayed as mean ± SD.
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Fig. 7. Targeting VEGFR2 reduced monocyte adhesion to brain endothelial cells in vitro. Expression of endothelial associated protein vonWillebrand Factor, and occludin-1, in
two different primary human brain microvascular endothelial cells (HBMEC) cultures and HUVEC (a). Representative images of fluorescent monocytes attached to cultured
brain endothelial monolayer following treatment with or without TNF-a or TNF-a+ ICAM-1 blocking antibody, scale bar = 100 lm (b). Effect of pre-treatment with a selective
VEGFR2 inhibitor ZM883231 (ZM, 20 nM, 1 h), VEGF-A165b (10 ng/ml, 24 h) , the VEGFR1&2 inhibitor PTK787 (PTK, 100 nM, 1 h) or an ICAM-1 blocking antibody (conc, time)
or non-specifc IgG on VEGF-A165a-induced monocyte adhesion, n = 9 (c). Effect of pre-treatment with VEGF-A165b (24 h), PTK787 (1h), an ICAM-1 blocking antibody or
ZM323881 (1h) on TNF-a-induced monocyte adhesion (d). Statistical analyses: 1-way analysis of variance + Dunnett’s multiple comparisons test: vs. untreated *p < 0.5,
**p < 0.01, ***p < 0.001, ****p < 0.0001; vs. respective control: #p < 0.5, ##p < 0.01, ###p < 0.001, ####p < 0.0001. Abbrev. Ab – antibody; HBMEC – human
brain microvascular endothelial cells; HUVEC – human umbilical vein endothelial cells; vWF – von Willebrand Factor; VEGF-A – vascular endothelial growth factor-A;
TNF-a – tumor necrosis factor-a; ICAM-1 – intercellular adhesion molecule-1. Adhesion assays: n = 9–20 (individual wells collated from three independent experiments).
Data displayed as mean ± SD.
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Before commencing a peripheral inflammatory pain model we
characterized the VEGFR2 knock-out in lung and spinal cord. The
VEGFR2 genomic KO product was detected only in CD31+ cells
from tamoxifen-treated Tie2CreERT2 vegfr2fl/fl mice, and not
(vehicle-treated Tie2CreERT2 vegfr2fl/fl (uninduced) mice or
Tie2CreERT2-negative (wildtype) mice, indicating VEGFR2 endothe-
lial cell knock-out (VEGFR2ECKO) (Supplementary Fig. 2). Tie2 and
VEGFR2 expression levels were analysed by flow cytometry in
CD31+ lung (Supplementary Fig. 2) and CD31+ spinal cord cells
(Supplementary Fig. 3). In both samples VEGFR2ECKO significantly
reduced the number of viable Tie2+ cells (lung, reduced by 21.1
± 6.3%, spinal cord reduced by 42.6 ± 8.3%) and the number of
Tie2+ cells expressing VEGFR2 (lung reduced by 48 ± 6.9%, spinal
cord 45.4 ± 12.1%) (Supplementary Figs. 2&3).
3.8. Inducible Tie2CreERT2-mediated VEGFR2 knock-out affected the
development of pain-associated behaviors in a model of inflammatory
arthritis
Hind paw mechanical stimulus thresholds were not affected by
tamoxifen treatment in either VEGFR2ECKO or vegfr2fl/fl:wt mice
compared with baseline or respective vehicle-treated control
groups over a 2-week period following the start of dosing (Supple-mentary Fig. 4a). CFA inflammation was induced in VEGFR2ECKO
and the two control groups [vegfr2fl/fl:Tie2CreERT2 mice treated
with vehicle (uninduced, Fig. 8) and vegfr2fl/fl:wt treated with
tamoxifen, Fig. 9] by peri-articular ankle joint injection. CFA caused
a significant drop in the ipsilateral hind paw mechanical stimulus
threshold measured in both control mouse groups from day two
onwards compared with respective baseline or sham injection
Figs. 8a & 9a). In VEGFR2ECKO mice, CFA caused a significant reduc-
tion in ipsilateral mechanical stimulus threshold only from day five
onwards which was significantly different from the uninduced
group on day two Fig. 8a) and the vegfr2fl/fl:wt + tamoxifen group
on days two and five Fig. 9a). CFA also caused a significant reduc-
tion in the contralateral hind paw mechanical threshold measured
in control mouse groups from day five onwards compared to
respective baseline or sham control. In contrast, VEGFR2ECKO mice
did not develop contralateral mechanical sensitivity Figs. 8b & 9b).
CFA caused a significant shift in weight bearing to the contralateral
hind paw in uninduced control mice compared to respective sham
animals on days two, five, eight and 14 yet a significant shift was
observed in the VEGFR2ECKO animals only on day five. On day
two there was a significant difference between VEGFR2ECKO and
both control groups Figs. 8c & 9c). All three groups developed a sig-
nificant increase in the ipsilateral tibiotarsal joint diameter follow-
ing CFA over the course of the experiment Figs. 8d &. 9d) and a
significant difference was observed only on day 14 between
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Fig. 8. Endothelial VEGFR2 knock-out affected pain behaviors in comparison to uninduced control animals. Ipsilateral (a) and contralateral (b) hind pawmechanical stimulus
threshold in control (uninduced) animals. In VEGFR2ECKO mice, the reduction in mechanical stimulus threshold was significantly delayed in (a) the ipsilateral hind paw and
significantly prevented in (b) the contralateral hind paw in comparison with uninduced control mice. A significant inhibition of the CFA-induced shift in weight bearing was
also observed on day 2 (c) and by day 14 there was a significant reduction in joint diameter (d). Mechanical allodynia 2 and 5 days following the start of recombinant human
VEGF-A165a treatment (8ng/g i.p. biweekly) (g). Statistical analyses: b-f, h: 2-way repeated measures analysis of variances + Dunnett’s multiple comparisons test; vs.
respective baseline (day 0): *p < 0.5, **p < 0.01, ***p < 0.001, ****p < 0.0001; vs. respective control at given time point: ##p < 0.01, ###p < 0.001, ####p < 0.0001; f: Student’s
t-test, *p < 0.05. a: n = 3; b: n = 10–11; c-f n = 5–6; g,h; n = 5. Abbrev. CFA, complete Freund’s adjuvant. Data displayed as mean ± SD.
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tion of the behavioral assessment, the level of VEGFR2 mRNA
was determined in CD31+ lung cells from the same mice to confirm
continued knock-out. VEGFR2 mRNA detected in KO mice was sig-
nificantly reduced (by 57.2 ± 4.3% of uninduced mice, n = 5, Sup-
plementary Fig. 4b).
In a separate experiment, knock-out and control mice were
treated with rhVEGF-A165a [8ng/g body weight i.p., known to result
in hind paw mechanical allodynia (Hulse et al., 2014)] 2 weeks
after tamoxifen treatment. Biweekly rhVEGF-A165a treatment
caused a significant reduction in hind paw mechanical threshold
Fig. 8e). In contrast, biweekly treatment of rhVEGF-A165a in
knock-out mice had no effect on mechanical threshold and this
was significantly different from control mice at the two time points
tested Fig. 8e).
Following the completion of the VEGFR2ECKO inflammatory
arthritis behavioral assay we investigated expression levels of
GFAP, ICAM-1 and CD11b in the dorsal horn (day 14 tissue).Peri-articular CFA caused an significant increase in the number
of dorsal horn CD31+ vessels associated with GFAP+ reactive
astrocytic end-feet (glio-vascular response) compared with sham
uninduced mice Fig. 10a,b,m,n, quantification in p). There was
also a significant increase in the number of vessels associated
with GFAP+ astrocytic end-feet in VEGFR2ECKO mice compared
with sham uninduced controls, however CFA treatment in
VEGFR2ECKO mice did not significantly increase this further
Fig. 10c,d, quantification in p). CFA caused a significant increase
in the number of CD11b+ cells associated with CD31+ vessels and
the number of ICAM-1+ / CD31+ vessels in uninduced mice com-
pared with sham Fig. 10e,f,i,j,o-r) but the same effects of CFA
were not observed in VEGFR2ECKO mice Fig. 10 g,h,k,l quantifica-
tion in q&r). There were no significant differences between the
ipsi- and contralateral sides within each group in either of the
analyses. A low number of CD11b+ cells were detected in the
dorsal horn parenchyma and CFA did not significantly affect this
(Supplementary Fig. 5).
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Pharmacological targeting of VEGFR2 affects nociception in a
number of preclinical models of pain (Hulse et al., 2014, 2015,
2016; Nesic et al., 2010; Lin et al., 2010; Nagai et al., 2014), but
the cellular location of the VEGFR2 involved in this process and
the underlying mechanism have not been clearly elucidated. Here
we provide evidence that inhibiting endothelial VEGFR2 disrupts
the development of secondary pain behavior in rats (systemic
pharmacological inhibition including an anti-VEGFR2 antibody
that would not freely cross the BBB/BSCB, Fig. 2) and in inducible
endothelial VEGFR2 knock-out mice (Fig. 9). Conversely, targeting
local VEGFR2 by intra-articular injection of anti-VEGFR2 agents
(Fig. 3) did not affect secondary mechanical allodynia indicating
that the anti-nociceptive effects of systemic VEGFR2 inhibition
are not elicited by an inhibitory mechanism at the site of inflam-
mation in the joint. The inhibition of secondary pain-like behaviors
(the spread of sensitivity) indicates an endothelial site of action in
the PNS and/or CNS. Systemic anti-VEGFR2 treatment reduced
endothelial activation and the number of CD11b+ microglia-like
cells in the lumbar spinal cord dorsal horn parenchyma (Figs. 4
and 5) and endothelial activation in the DRG (Fig. 6) in response
to knee joint inflammation. Furthermore inducible endothelial
knock-out prevented glio-vascular activation in response to ankle
joint inflammation. These results highlight that spinal and DRGmicrovasculature may contribute to the development of nocicep-
tive processes in peripheral inflammation, and indicate the impor-
tance of endothelial VEGFR2 in the spread of pain. Further work
using this model could investigate whether the observed spinal
cord glio-vascular response is restricted to segments correspond-
ing to the inflamed joint or is more widespread within the CNS.
The outcome would indicate either a sensory afferent-mediated
neurogenic glio-vascular response or CNS glio-vascular activation
in response to systemic inflammation. The absence of ICAM-1+
upregulation in the contralateral DRG indicates that the observed
spinal glio-vascular activation in both sides of the cord was in
response to CFA-induced ipsilateral peripheral drive as opposed
to a widespread vascular response to systemic inflammation. The
significant effects observed in the contralateral spinal cord are
likely to be a consequence of commissural neuronal signaling
which includes somatosensory/nociceptor signaling (Comer et al.,
2015).
Reactive glia and monocyte/macrophage infiltration in the CNS
are common features of chronic neurodegenerative (Rezai-Zadeh
et al., 2009) and autoimmune diseases (Winer, 2001; Ziff, 1989),
and CNS injuries such as stroke (Gronberg et al., 2013; Michell-
Robinson et al., 2015). Reactive astrocytes and microglia-like cells
are found in the spinal dorsal horn in patients with longstanding
complex regional pain syndrome (Del Valle et al., 2009). In rat
peripheral sciatic nerve injury, a significant proportion of dorsal
Fig. 10. VEGFR2ECKO inhibited glio-vascular activation in thedorsal hornof CFA treatedmice. Peri-articular CFA caused an significant increase in thenumber of dorsal hornCD31+
vessels associatedwithGFAP+ reactive astrocytic foot processes (glio-vascular response) comparedwith sham inuninducedmice (a,b, quantification inp). Therewas a significant
increase in the number of vessels associated with GFAP+ astrocytic foot processes in sham-treated VEGFR2ECKO compared with sham-treated uninduced controls, however CFA
treatment in VEGFR2ECKOmice did not significantly increase this further (c,d, quantification in p). CFA caused a significant increase in the number of CD11b+ cells associatedwith
CD31+ vessels and the number of ICAM-1+ vessel structures in uninduced mice compared with sham (e,f,i,j quantification in q&r) but the same effects were not observed in
VEGFR2ECKO (g,h,k,l quantification in q&r). Higher magnification images of GFAP+ reactive astrocytic end feet (m, n, arrowheads denote GFAP+/CD31+ vessel structures), CD11b+
cells associated with vessel (n, arrows denote CD11b+ cells associated with CD31+ vessel structures, dotted arrow denotes a parenchyma CD11b+ cell) and ICAM-1+ vessels
(o, arrowheads denote ICAM-1+/CD31+ vessel structures). Three statistical analyseswere performed: 2-wayANOVA + Bonferronimultiple comparisons test: vs. uninduced sham
con *p < 0.05, ** p < 0.01; KO CFA vs KO sham control – no significance; contra vs. ipsi of respective group – no significane; n = 3–6. Data displayed as mean ± SD.
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derive from circulating monocytes/macrophages that had migrated
into the spinal cord parenchyma and differentiated into a reactive
microglia-like phenotype (Zhang et al., 2007; Echeverry et al.,
2011). For this process to occur, the spinal cord endothelium needs
to be stimulated to express adhesion molecules for monocyte
transmigration across the BSCB. Furthermore both residential
microglia and peripheral monocytes are required for the transition
from acute to chronic pain after nerve injury providing further evi-
dence that peripheral immune cells are involved in the develop-
ment of chronic pain (Peng et al., 2016). Our findings suggest
transendothelial migration of CD11b+ monocytes into the spinal
dorsal horn parenchyma occurs following peripheral inflammation
and is controlled by vascular VEGFR2-mediated ICAM-1-induced
adhesion. Circulating monocytes also transmigrate across the
blood-nerve barrier in sensory ganglia and take on a
macrophage-like phenotype, in a preclinical inflammatory pain
model (Segond von Banchet et al., 2009), and CD68+ macrophages
migrate into DRG in antigen-induced arthritis progression
(Jochmann et al., 2015). We did not observe CD68+ cells in DRG
despite increased vascular ICAM-1 expression. Our findings on
GFAP, CD11b and ICAM-1 expression in both sides of the spinal
cord and ipsilateral DRG indicate that nervous system-
endothelial VEGFR2 promotes endothelial ICAM-1 expression in
the dorsal horn and DRG in inflammatory arthritis. CD11b is
expressed on reactive microglia (Sedgwick et al., 1998) and also
neutrophils, monocytes, natural killer cells and subsets of lympho-
cytes (Springer, 1990; Kawai et al., 2005). CD11b contributes to
firm leukocyte adhesion to activated endothelium via interaction
with ICAM-1, sub-endothelium basement membrane components
and pericytes (Thompson and Matsushima, 1992; Lundgren-
Akerlund et al., 1993; Bohnsack et al., 1990; Ding et al., 1999;
Schmitt et al., 2018). The reduction of CD11b+ cells in the rat spinal
cord parenchyma by day 11 suggests that the reactive microvascu-
lature contributes to transmigration of CD11b+ cells into the par-
enchyma and/or the activation of residential microglia through a
VEGFR2-mediated mechanism. In stroke models, brain pericytes
release from the microvasculature, migrate into the parenchyma
and differentiate into a CD11b+ microglia-like phenotype (Ozen
et al., 2014). In the present study dorsal horn glio-vascular activa-
tion could trigger a similar process providing an alternative source
for the increase in CD11b+ cells within the dorsal horn parench-
yma. In our inducible endothelial VEGFR2 KO study a significant
increase in the number of parenchymal microglia-like cells was
not detected in the dorsal horn 14 days after CFA administration
in uninduced control mice. However a significant increase in the
number of CD11b+ cells associated with vessels and ICAM-1+ vessel
structures were both observed, which endothelial VEGFR2 KO pre-
vented. These results implicate vessel-associated CD11b+ cells and
ICAM-1 vessel expression in the central changes that occur follow-
ing peripheral inflammation and provide further evidence that
endothelial VEGFR2 may drive a vascular mechanism that pro-
motes the development of secondary pain. In our rat study the
number of CD11b+ cells associated with the dorsal horn microvas-
culature on day 8 was not different between the inflamed groups
suggesting that the anti-VEGFR2 treatments did not affect the mat-
uration and release of immune cells into the circulation through an
inhibitory mechanism in bone marrow. Furthermore we could not
detect a significant population of Tie2+/VEGFR2+ peripheral
mononuclear cells in the uninduced mice (data not shown) and
VEGFR2ECKO knock-out mice also show no change in the number
of CD11b+ cells isolated from spleen (Ved et al., under review).
Therefore we think the KO is unlikely to have caused a decrease
in circulating CD11b+ immune cells that consequently reduced
CD11b+ cell transmigration into the spinal parenchyma, thussupporting an endothelial site of action of anti-VEGFR2. The
in vitro inhibition of THP-1 monocyte adhesion to brain microvas-
cular endothelial cells by anti-VEGFR2 compounds supports the
hypothesis that in vivo VEGFR2 inhibition may reduce CD11b+
monocytic adhesion and infiltration or pericytic migration into
the spinal cord through a reduction in VEGF-A-mediated vascular
activation and ICAM-1 expression.
VEGF-A protein is increased in the serum of rheumatoid arthritis
patients (Nakahara et al., 2003), and is upregulated in painful dis-
ease models such as chronic constriction injury (Lin et al., 2010;
Tang et al., 2009) and type I diabetes (Samii et al., 1999). Inhibition
of VEGFR2 signaling decreases pain-associated responses (Lin et al.,
2010). VEGF-A165b, a splice isoform of VEGF-A is a partial agonist of
vascular endothelial growth factor receptor-2 (VEGFR2) and com-
petes with VEGF-A165a for binding to VEGFR2 (Kawamura et al.,
2008). Systemic VEGF-A165b administration is also able to reduce
neuronal damage and pain-associated responses in nerve injury
(Hulse et al., 2014; Beazley-Long et al., 2013) and type I diabetes
models (Hulse et al., 2015). Intrathecal blockade of VEGF-A or
VEGFR2 inhibits pain responses in both pain models and normal
animals (Zhang et al., 2011; Hess et al., 2011; Boettger et al.,
2010), and intrathecal delivery of rhVEGF-A165a is pro-nociceptive
in normal animals (Hulse et al., 2016) indicating central nociceptive
actions of VEGF-A/VEGFR2. Combined with our findings, there is
compelling evidence that systemic anti-VEGFR2 therapy could be
of analgesic benefit to patients with inflammatory arthritis, even
when disease is controlled by anti-TNF-a treatment.
The time points at which we observed activated vessels are con-
sistent with the spinal endothelial activation being a consequence
of nociceptor-driven central changes, as opposed to an acute sys-
temic inflammatory response, as both increased peripheral drive
(Schaible and Schmidt, 1988; Andrew and Greenspan, 1999) and
central sensitisation (Neugebauer and Schaible, 1988) occur within
hours. Furthermore the increase in the number of GFAP+ astrocytic
end-feet wrapping ICAM-1+ vessels in the dorsal horn and the tim-
ing of these changes provides a likely astrocyte-mediated mecha-
nism for microvessel activation in response to inflammation-
driven neuronal input. Such glia-vascular co-activation, with
ICAM-1 expression, is also found in specific brain regions in acute
inflammation, along with immune cell infiltration and is suggested
to contribute to breakdown of blood-brain barrier integrity in
inflammatory pain (Willis et al., 2008; Huber et al., 2006). Our find-
ings are the first to show a function for endothelial VEGFR2 in
peripheral inflammation-driven glio-vascular activation. If deplet-
ing circulating monocytes produces a similar anti-nociceptive
effect to anti-VEGFR2 in inflammatory arthritis this would provide
direct evidence of transmigrating pro-nociceptive immune cells
that is mediated by VEGFR2.
The acute anti-nociceptive effect of anti-VEGFR2 treatment (<8
days) cannot be attributable to inhibition of transendothelial
migration in the dorsal horn as this preceded the increase in
CD11b+ microglia in the dorsal horn. Systemic and local injection
of rhVEGF165a can directly drive nociceptor activity (Hulse et al.,
2014). It is possible therefore that the acute anti-nociceptive effect
of systemic anti-VEGFR2 was a consequence of direct sensory neu-
ronal inhibition (Hulse et al., 2014), and/or an indirect anti-
nociceptive effect through the inhibition of endothelial VEGFR2
in sensory nerve, ganglia and/or CNS at a time prior to day eight.
In the present study inducing endothelial VEGFR2 knock-out pre-
vented the acute pro-nociceptive effect of systemic rhVEGF-A165a
in the absence of inflammation. When considered with the anti-
nociceptive effect of receptor inhibition, these findings lead us to
conclude that VEGF-A165a working through endothelial VEGFR2
and endothelial activation, is involved in the initial nociceptive
processes underpinning the development of secondary
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transendothelial migration of immune cells into the dorsal horn.
VEGFR2 knock-out is embryonically lethal due to severe vascu-
lar defects (Shalaby et al., 1995) therefore to eludicate the site of
action of anti-VEGFR2 we generated and characterized an induci-
ble, Tie2-specific VEGFR2 knock-out mouse, enabling the targeting
of endothelial VEGFR2 in the adult mouse in a peripheral inflam-
mation pain study. First we characterised the inducible
Tie2CreERT2 VEGFR2 knock-out at DNA, RNA and protein levels in
the lung, and protein level in the spinal cord revealing a significant
reduction of VEGFR2 expression in endothelial (CD31+/Tie2+) cells.
VEGFR2ECKO caused a significant reduction in viable CD31+/Tie2+
cells (in both lung and spine) indicating an effect on endothelial
viability. VEGFR2ECKO also caused a significant reduction in VEGFR2
expression by CD31+/Tie2+ cells (both lung and spine). The reduc-
tion in endothelial VEGFR2 expression induced by the knock-out
is therefore likely to be significantly underestimated, as a result
of additional loss of Tie2+/VEGFR2+ cells. The VEGFR2ECKO knock-
out mice also display aberrant spinal cord microvasculature mor-
phology with a decrease in microvessel diameter and volume
(Ved et al., under review) supporting a survival role for VEGFR2
in the adult transgenic mice.5. Conclusions
Inflammatory arthritis causes glio-vascular activation, endothe-
lial ICAM-1 expression and an increase in parenchymal CD11b+
microglia-like cells in the dorsal horn of the lumbar spinal cord.
Furthermore targeting endothelial VEGFR2 is anti-nociceptive in
inflammatory arthritis, and reduces vascular activation and the
number of CD11b+ microglia-like cells in the dorsal horn. The asso-
ciation between the reduction of dorsal horn endothelial activation
and parenchymal CD11b+ cells, and the spread of mechanical sen-
sitivity has led us to propose a novel nociceptive mechanism:
spinal cord glio-vascular activation promotes transendothelial
migration of pro-nociceptive immune cells into neural parench-
yma and contributes to central sensitization and the spread of
inflammatory pain. In addition we hypothesise that increased
VEGF-A levels in the serum of people with rheumatoid arthritis
could activate neural microvasculature and promote transmigra-
tion of immune cells, thus contributing to central sensitization
and potentially the development of a chronic pain state. Our
results indicate that VEGFR2 inhibitors to prevent vascular action
and immune cell translocation could be a new additional therapeu-
tic strategy for rheumatoid arthritis patients as an adjunct to exist-
ing disease-modifying therapies.Acknowledgements
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